At-Home Health Testing Meets Scientific Rigor
At-home health testing has often been clouded by exaggerated claims and, in some cases, outright fraud. However, German startup TimeTeller is charting a different course. Specializing in a saliva test kit designed to help individuals understand their circadian rhythms, TimeTeller is led by CEO Angela Relógio, whose background and approach sharply contrast with infamous figures like Theranos’ Elizabeth Holmes.
Relógio’s credentials are impressive and integral to the company’s credibility. As a physicist-engineer and molecular biologist, she has spent years in Germany researching oncology, circadian biology, and systems medicine before transitioning from academia to entrepreneurship. Her scientific rigor is evident in her cautious communication about what TimeTeller’s test currently can and cannot achieve, emphasizing transparency over hype.
The Science Behind TimeTeller
It would be tempting to oversell the test’s capabilities, especially given that Relógio’s surname means “clock” in Portuguese—a fitting metaphor for the company’s mission. TimeTeller’s promise lies in its potential to optimize cancer treatment by aligning it with a patient’s internal biological clock, a concept supported by emerging research showing that timing treatments can reduce side effects and improve outcomes (source).
However, the company operates on two timelines: the immediate availability of its direct-to-consumer kit and the longer-term goal of integrating personalized circadian data into clinical decision-making. The current test kit is not designed to enable patients to self-determine the optimal timing for their medications. As Relógio explains, “That is something that we need to calculate for every single medicine; we do that in the context of clinical studies.” This distinction underscores the company’s commitment to responsible science and patient safety.
Expanding Applications and Market Demand
TimeTeller initially began accepting direct orders in response to interest from longevity clinics, which focus on healthy aging and recognize the value of personalized circadian rhythm data for tailoring advice on sleep, nutrition, light exposure, and physical activity. Beyond oncology, the technology holds promise for managing metabolic disorders such as diabetes, neurodegenerative diseases like Alzheimer’s, as well as improving overall human performance and women’s health.
Nonetheless, cancer remains the core mission. Relógio’s pivotal insight came during her cancer research when she observed patients frequently starting or stopping treatment due to side effects. “As a scientist, that was just impossible to watch, particularly when I was convinced that part of the problem might not only be what treatment we give, but when we give it,” she said. This observation motivated her to develop the circadian rhythm test central to TimeTeller’s offering and to transition from academic research to entrepreneurship.
Building a Trustworthy Company
Demonstrating personal conviction, Relógio funded TimeTeller’s first patent herself, driven by a desire to translate her scientific discovery into real-world benefits rather than leaving it confined to academic journals. The startup originated at Berlin’s Charité university hospital but later relocated to Medical School Hamburg. This move provided critical access to patients and funding sources, as well as a safety net for the small team of 10 employees should financial challenges arise.
The company’s trustworthiness is further reflected in its strategic partnerships. Co-founder Benjamin Dose, a biochemist and market access specialist, helped secure a collaboration with Techniker Krankenkasse, one of Germany’s largest health insurers. Initially, this partnership reimbursed the cost of the TimeTeller test for a subset of cancer patients, with plans to expand coverage to more than 12 million members, as Relógio confirmed.
The Future of Precision Medicine: Timing is Everything
While the direct-to-consumer test currently offers valuable insights mainly for longevity and wellness contexts, TimeTeller is paving the way for a future where the question of “when” becomes central to precision medicine. As Relógio stated during her appearance at TechCrunch Disrupt, “almost every process in our body is timed.” By harnessing circadian biology, TimeTeller aims to transform how treatments are personalized, making timing as critical a factor as dosage or drug type.
For patients and clinicians alike, this represents a paradigm shift that could improve treatment tolerability and efficacy across numerous conditions, especially cancer. As research and clinical validation progress, TimeTeller’s approach exemplifies how scientifically grounded innovation can restore trust in at-home health testing and empower individuals with actionable, personalized health data.
You aren’t too late to join the action at Disrupt. Come for the headliners; stay to see who wins this year’s no-strings check from TechCrunch — and the attention of the hundreds of VCs in attendance.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
Read more Here.
